LabCorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.
Values obtained with different assay methods should not be used interchangeably in serial testing. It is recommended that only one assay method be used consistently to monitor each patient's course of therapy. This procedure does not provide serial monitoring; it is intended for one-time use only. If serial monitoring is required, please use the serial monitoring number 480137 to order.
6 - 10 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
0.3 mL (Note: This volume does not allow for repeat testing.)
Red-top tube or gel-barrier tube
Transfer separated serum to a plastic transport tube as quickly as possible after the clot has formed (within 30 minutes of collection).
Hemolysis; plasma specimen; recently administered isotopes
NSE is a useful adjunct in the monitoring of patients with small cell lung cancer (SCLC).
NSE is not a screening test. Results of this test are labeled for research purposes only by the assay's manufacturer. The performance characteristics of this assay have not been established by the manufacturer. The result should not be used for treatment or for diagnostic purposes without confirmation of the diagnosis by another medically established diagnostic product or procedure. The performance characteristics were determined by LabCorp.
Enzyme immunoassay (EIA)
Neuron specific enolase is one of the five isozymes of the glycolytic enzyme, enolase. This enzyme is released into the CSF when neural tissue is injured. Neoplasms derived from neural or neuroendocrine tissue may release NSE into the blood. The test may have value in predicting response to therapy. In a group of 13 patients with small cell carcinoma of lung, very high levels of NSE (≥100 ng/mL, mean of 490 ng/mL) were found in seven of eight responders. Levels <100 ng/mL (mean 28 ng/mL) were found in the remaining six patients, only two of whom were responders. These values are from samples obtained during the first three-day course of chemotherapy. There is evidence that the level of serum neuron-specific enolase correlates with tumor burden.1-3 Increase occurs more commonly and is at higher levels in advanced stage than in limited stage disease.3 The enzyme has been elevated in sera of all patients with three or more sites of metastases.1
Serum NSE levels are increased in cases of neuroblastoma,4 but also in other childhood tumors.5 Levels >100 ng/mL in children are, however, highly suggestive of advanced neuroblastoma. Use of NSE to monitor treated neuroblastoma patients has not been found to be a sensitive index of residual tumor.5 NSE levels may also be increased in some patients with seminoma6 and some patients with uremia who have been on dialysis.7
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|140624||Neuron-specific Enolase, Serum||57371-7||140606||Neuron-specific Enolase, Serum||ng/mL||57371-7|
© 2020 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
The LOINC® codes are copyright © 1994-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf